BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 7750284)

  • 41. A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ER alpha.
    Larrea F; García-Becerra R; Lemus AE; García GA; Pérez-Palacios G; Jackson KJ; Coleman KM; Dace R; Smith CL; Cooney AJ
    Endocrinology; 2001 Sep; 142(9):3791-9. PubMed ID: 11517155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
    Dibbelt L; Knuppen R; Jütting G; Heimann S; Klipping CO; Parikka-Olexik H
    Contraception; 1991 Jan; 43(1):1-21. PubMed ID: 1825969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells.
    Pasapera AM; Gutiérrez-Sagal R; García-Becerra R; Ulloa-Aguirre A; Savouret JF
    Endocrine; 2001 Dec; 16(3):217-25. PubMed ID: 11954666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor.
    Herkert O; Kuhl H; Sandow J; Busse R; Schini-Kerth VB
    Circulation; 2001 Dec; 104(23):2826-31. PubMed ID: 11733402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
    Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.
    Attardi BJ; Page ST; Hild SA; Coss CC; Matsumoto AM
    J Steroid Biochem Mol Biol; 2010 Feb; 118(3):151-61. PubMed ID: 19941958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy.
    Louw-du Toit R; Perkins MS; Hapgood JP; Africander D
    Biochem Biophys Res Commun; 2017 Sep; 491(1):140-146. PubMed ID: 28711501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914.
    Attardi BJ; Burgenson J; Hild SA; Reel JR; Blye RP
    Mol Cell Endocrinol; 2002 Feb; 188(1-2):111-23. PubMed ID: 11911951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selectivity and potency of the retroprogesterone dydrogesterone in vitro.
    Rižner TL; Brožič P; Doucette C; Turek-Etienne T; Müller-Vieira U; Sonneveld E; van der Burg B; Böcker C; Husen B
    Steroids; 2011 May; 76(6):607-15. PubMed ID: 21376746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women.
    Kuhnz W
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 2):2120-7. PubMed ID: 2124087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of changes in the concentration of sex hormone-binding globulin in human serum on the protein binding of the contraceptive steroids levonorgestrel, 3-keto-desogestrel and gestodene.
    Kuhnz W; Schütt B; Woloszczak R
    J Steroid Biochem Mol Biol; 1994 Apr; 48(5-6):573-80. PubMed ID: 8180122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S; Charoenvisal C; Banharnsupawat L; Singhakovin S; Kaewsuk O; Punnahitanont S
    Contraception; 1995 Apr; 51(4):225-9. PubMed ID: 7796587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of antiandrogenic progestins, chlormadinone and cyproterone acetate, and the estrogen 17α-ethinylestradiol (EE2), and their mixtures: Transactivation with human and rainbowfish hormone receptors and transcriptional effects in zebrafish (Danio rerio) eleuthero-embryos.
    Siegenthaler PF; Bain P; Riva F; Fent K
    Aquat Toxicol; 2017 Jan; 182():142-162. PubMed ID: 27907851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
    Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
    Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.
    Sasagawa S; Shimizu Y; Kami H; Takeuchi T; Mita S; Imada K; Kato S; Mizuguchi K
    Steroids; 2008 Feb; 73(2):222-31. PubMed ID: 18061638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD; Lawrenson RA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.